Biotech voic­es: Al­ler­gan CEO Saun­ders isn’t slow­ing down on a brisk pace of biotech deal­mak­ing

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

Last year, Al­ler­gan did 12 “step­ping-stone” deals, snap­ping up a whole slate of new de­vel­op­ment pro­grams, ex­pand­ing its pipeline and set­ting the pace as one of the busiest deal­mak­ers in biotech.

2017 shouldn’t be much dif­fer­ent.

Dur­ing Wednes­day’s Q&A with an­a­lysts, CEO Brent Saun­ders said that Al­ler­gan spent $5 bil­lion on trans­ac­tions last year – $3 bil­lion of that go­ing for Life­Cell – with a heavy em­pha­sis on ac­cre­tive pacts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER